Results 31 to 40 of about 2,052,688 (283)

Chimeric antigen receptor natural killer cell therapy for solid tumors: mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Experimental Biology and Medicine
Natural killer (NK) cells represent a fundamental component of the innate immune system, endowed with the ability to identify and eradicate virus-infected and malignant cells.
Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +18 more
doaj   +1 more source

Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells

Frontiers in Genetics, 2020
The term cancer stem cell (CSC) starts 25 years ago with the evidence that CSC is a subpopulation of tumor cells that have renewal ability and can differentiate into several distinct linages.
Rowa Y. Alhabbab
doaj   +1 more source

In-depth analysis of the safety of CAR-T cell therapy for solid tumors

Frontiers in Immunology
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy.
Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiexiong Wu, Ye Jin, Ye Jin, Ye Jin, Ye Jin, Ye Jin, Zhu Zheng, Zhu Zheng, Zhu Zheng, Zhu Zheng, Zhu Zheng, Ting Su, Ting Su, Ting Su, Ting Su, Ting Su, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Jiaxin Bei, Jiaxin Bei, Jiaxin Bei, Jiaxin Bei, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +33 more
doaj   +1 more source

A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer. [PDF]

Adv Sci (Weinh)
A dual‐transmembrane Bicephali CAR‐T platform simultaneously targets CD276 and NKG2D ligands to address antigen heterogeneity in non‐small cell lung cancer. By improving immune synapse formation, mitochondrial fitness, antioxidant capacity, and stem‐like persistence, this design enhances durable tumor control and provides a versatile strategy to ...
Wang L, Zhang Y, Peng S, Hou C, Guo H, Zhou T, Chang AH, Yan L, Xiong W.   +8 more
europepmc   +2 more sources

Influence of Patient Characteristics on Chimeric Antigen Receptor T Cell Therapy in B-cell Acute Lymphoblastic Leukemia

, 2020
Dataset of the study “Influence of Patient Characteristics on Chimeric Antigen Receptor T Cell Therapy in B-cell Acute Lymphoblastic Leukemia”
Jiakui Zhang (8521494), Zhimin Zhai (8521391), Qianshan Tao (8521500), Furun An (8521383), Weiwei Zhu (8521515), Xiaotong Song (8521521), Hui Qin (8521517), Fan Wu (8521491), Yanjie Ruan (8521508), Yansheng Wang (8521518), Zhenqing Feng (8521520), Yuanyuan Shen (8521505), Huiping Wang (8521482), Qing Zhang (8521509), Yingwei Li (8521503), Ying Pan (8521512), Zhenyun Liu (8521488)   +16 more
core   +2 more sources

A TCR-based Chimeric Antigen Receptor

Scientific Reports, 2017
Effector T cells equipped with engineered antigen receptors specific for cancer targets have proven to be very efficient. Two methods have emerged: the Chimeric Antigen Receptors (CARs) and T-cell Receptor (TCR) redirection.
Even Walseng, Hakan Köksal, Ibrahim M. Sektioglu, Anne Fåne, Gjertrud Skorstad, Gunnar Kvalheim, Gustav Gaudernack, Else Marit Inderberg, Sébastien Wälchli   +8 more
doaj   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Natural killer cell immunotherapy in glioblastoma

Discover Oncology, 2022
Glioblastoma (GBM) is one of the most difficult cancers to treat because GBM has the high therapeutic resistance. Recently, immunotherapies for GBM have been used instead of conventional treatments.
Hamed Hosseinalizadeh, Mehryar Habibi Roudkenar, Amaneh Mohammadi Roushandeh, Yoshikazu Kuwahara, Kazuo Tomita, Tomoaki Sato   +5 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer

BMC Cancer, 2018
Background Salivary gland cancers are not sensitive to conventional radiotherapy or chemotherapy regimens. Therefore, the development of a new treatment strategy is of critical importance for improving the prognosis.
Yuji Makita, Naoki Kunii, Daiju Sakurai, Fumie Ihara, Shinichiro Motohashi, Akane Suzuki, Toshinori Nakayama, Yoshitaka Okamoto   +7 more
doaj   +1 more source